We are live on ! Find out more
OIM

Oracle Investment Management Portfolio holdings

AUM $168M
1-Year Est. Return 42.86%
This Fund
S&P 500
This Quarter Est. Return
+11.52%
1 Year Est. Return
+42.86%
3 Year Est. Return
+864.89%
5 Year Est. Return
+1,153.35%
10 Year Est. Return
+22,228.86%
AUM
$803M
AUM Growth
+$77.7M
Cap. Flow
+$364M
Cap. Flow %
45.26%
Top 10 Hldgs %
87.76%
Holding
46
New
17
Increased
9
Reduced
5
Closed
6

Top Buys

Rank Stock Value
1
VIR icon
Vir Biotechnology
VIR
+$20.6M
2
QDEL icon
QuidelOrtho
QDEL
+$9.35M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$8.57M
4
GH icon
Guardant Health
GH
+$8.32M
5
XBIT icon
XBiotech
XBIT
+$5.58M

Top Sells

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$10.3M
2
CAPR icon
Capricor Therapeutics
CAPR
+$5.98M
3
DMTK
DermTech, Inc. Common Stock
DMTK
+$1.53M
4
MOTS
Motus GI Holdings, Inc. Common Stock
MOTS
+$631K
5
BDSX icon
Biodesix
BDSX
+$519K

Sector Composition

Rank Sector Weight
1 Healthcare 98.99%
2 Energy 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDSX icon
26
Biodesix
BDSX
$248M
$1.49M 0.19%
9,042
-2,734
-23% -$519K
VIR icon
27
CALL
Vir Biotechnology
VIR
$1.49B
$1.2M 0.15%
+383,700
New +$16.6M
PTIX
28
DELISTED
Performance Technologies
PTIX
$935K 0.12%
+8,929
New +$1.07M
QQQ icon
29
PUT
Invesco QQQ Trust
QQQ
$484B
$895K 0.11%
+300,000
New +$110M
BIIB icon
30
Biogen
BIIB
$30.7B
$683K 0.09%
2,412
– –
LLY icon
31
CALL
Eli Lilly
LLY
$1.06T
$680K 0.08%
+100,000
New +$24.7M
VTNR
32
DELISTED
Vertex Energy, Inc
VTNR
$472K 0.06%
90,000
– –
MDGL icon
33
CALL
Madrigal Pharmaceuticals
MDGL
$11.8B
$426K 0.05%
+63,000
New +$5.44M
XBIT icon
34
XBiotech
XBIT
$69.2M
$275K 0.03%
+350,000
New +$5.58M
SEM
35
CALL
DELISTED
Select Medical
SEM
$193K 0.02%
+48,442
New +$962K
BCRX icon
36
CALL
BioCryst Pharmaceuticals
BCRX
$2.4B
$176K 0.02%
+150,000
New +$2.37M
OPK icon
37
CALL
Opko Health
OPK
$1.02B
$145K 0.02%
+473,800
New +$1.76M
PFE icon
38
CALL
Pfizer
PFE
$153B
$98K 0.01%
+750,000
New +$33.2M
AGEN
39
CALL
Agenus
AGEN
$290M
$53K 0.01%
+5,095
New +$576K
PACB icon
40
CALL
Pacific Biosciences
PACB
$370M
$50K 0.01%
+43,700
New +$1.29M
CAPR icon
41
Capricor Therapeutics
CAPR
$237M
– –
-1,166,249
Closed -$5.98M
OPK icon
42
PUT
Opko Health
OPK
$1.02B
– –
-667,800
Closed -$334K
VIR icon
43
PUT
Vir Biotechnology
VIR
$1.49B
– –
-196,700
Closed -$1.31M
XBI icon
44
State Street SPDR S&P Biotech ETF
XBI
$10.3B
– –
-76,200
Closed -$10.3M
XBI icon
45
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
– –
-825,000
Closed -$3.9M
BHVN
46
PUT
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-248,200
Closed -$1.82M
1
2

Similar funds

EECFX
EnCap Energy Capital Fund XII Houston, Texas $169M AUM
PW
Pandora Wealth Oakbrook Terrace, Illinois $165M AUM 18.5% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
AIMU
Allianz Investment Management US Minneapolis, Minnesota $160M AUM 4.75% 1-Year Est. Return
HIA
Harvest Investment Advisors Tallahassee, Florida $176M AUM
ACA
AG Campbell Advisory Baltimore, Maryland $158M AUM
CWA
Clearview Wealth Advisors Salem, Oregon $158M AUM 14.25% 1-Year Est. Return
SW
Schulz Wealth Mansfield, Texas $156M AUM 13.29% 1-Year Est. Return

Oracle Investment Management's Q3 2021 Portfolio in Review

As of Q3 2021, Oracle Investment Management held 46 positions worth $803M, up 11% from $726M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Oracle Investment Management deployed $364M of net new capital in Q3 2021, opening 17 new positions and adding to 9 existing holdings. Its largest new stake was Atea Pharmaceuticals: 309,126 shares worth $10.8M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Energy.

On the sell side, the largest reduction was DermTech, Inc. Common Stock, an estimated $1.53M trimmed.

  • Oracle Investment Management's largest Q3 2021 buy was Atea Pharmaceuticals: 309,126 shares worth $10.8M.
  • Oracle Investment Management added most to Vir Biotechnology in Q3 2021, an estimated $20.6M increase.
  • Oracle Investment Management's biggest Q3 2021 reduction was DermTech, Inc. Common Stock, cutting an estimated $1.53M.
  • Oracle Investment Management fully exited State Street SPDR S&P Biotech ETF in Q3 2021, selling an estimated $10.3M.
  • Oracle Investment Management's ten largest holdings make up 88% of its $803M portfolio in Q3 2021.
  • Oracle Investment Management opened 17 new positions and closed 6 in Q3 2021.
  • Oracle Investment Management's portfolio value rose 11% quarter-over-quarter to $803M.

Based on Oracle Investment Management's 13F filing for Q3 2021, filed 15 Nov 2021.